Comparative Study of Montelukast with Dexamethasone for Possible Protection against Endotoxic Effect of Lipopolysaccharide in Male Mice
DOI:
https://doi.org/10.31351/vol34iss4pp172-183Abstract
Endotoxic septic shock (ESS) is a serious clinical syndrome caused by gram-negative bacterial infections. ESS refers to infected patients with high bloodstream endotoxin levels and activity and a high rate of cardiovascular, pulmonary, hepatic, and renal failure. The endotoxin in the bacterial cell wall can evoke neutrophil monocytes and secrete inflammatory mediators like cytokines, nitric oxide, histamine, and bradykinin, causing local and systemic inflammation, severe vasodilation, endothelial dysfunction, increased capillary permeability, vascular fluid extravasation, and disseminated intravascular coagulation. Mice were utilized as experimental animals for research by inducing endotoxemia or a septic-like condition that closely simulates septic shock in humans via administering lipopolysaccharide (LPS) isolated from a particular bacterial strain at an appropriate dose. This study examined whether montelukast and dexamethasone protect male mice from LPS-induced endotoxicity. Twenty-eight Albino mice were randomly assigned to four groups (seven per group): Group I (control) mice were given 0.25–0.5 ml of distilled water by oral gavage once daily for a week and euthanized on the 8th day. Group II mice received 10 mg/kg intraperitoneal LPS and were euthanized on the second day. Group III mice received oral gavage dexamethasone 2.5 mg/kg once daily for a week. Two hours following the final dosage, LPS was given and euthanized on the 8th day. Group IV mice received oral gavage montelukast (20 mg/kg) once daily for a week. Two hours after the last dose, LPS was given and euthanized on the 8th day. Results show that pretreatment with both drugs lowers serum TNF-α, IL-6, RANK, and OPG levels, as well as cathepsin-G and neutrophil elastase gene expression. In conclusion, montelukast may have a promising protective effect from LPS-induced endotoxicity and may be an option as a protective drug from inflammatory consequences in humans.
How to Cite
Publication Dates
Received
Revised
Accepted
Published Online First
References
Setiawati R, Rahardjo P. Bone development and growth. Osteogenesis and bone regeneration. 2019 Apr 24;10.
Holliday LS, Patel SS, Rody Jr WJ. RANKL and RANK in extracellular vesicles: Surprising new players in bone remodeling. Extracellular vesicles and circulating nucleic acids. 2021;2:18.
Bolamperti S, Villa I, Rubinacci A. Bone remodeling: an operational process ensuring survival and bone mechanical competence. Bone Research. 2022 Jul 18;10(1):48.
Casanova-Acebes M, Nicolás-Ávila JA, Li JL, García-Silva S, Balachander A, Rubio-Ponce A, Weiss LA, Adrover JM, Burrows K, A-González N, Ballesteros I. Neutrophils instruct homeostatic and pathological states in naive tissues. Journal of Experimental Medicine. 2018 Nov 5;215(11):2778-95.
Deniset JF, Surewaard BG, Lee WY, Kubes P. Splenic Ly6Ghigh mature, and Ly6Gint immature neutrophils contribute to the eradication of S. pneumoniae. Journal of Experimental Medicine. 2017 May 1;214(5):1333-50.
Foster DM, Kellum JA. Endotoxic Septic Shock: Diagnosis and Treatment. International Journal of Molecular Sciences. 2023 Nov 10;24(22):16185.
Kellum JA, Ronco C. The role of endotoxin in septic shock. Critical Care. 2023 Oct 19;27(1):400.
Rudd KE, Johnson SC, Agesa KM, Shackelford KA, Tsoi D, Kievlan DR, Colombara DV, Ikuta KS, Kissoon N, Finfer S, Fleischmann-Struzek C. Global, regional, and national sepsis incidence and mortality, 1990–2017: analysis for the Global Burden of Disease Study. The Lancet. 2020 Jan 18;395(10219):200-11.
Vincent JL, Jones G, David S, Olariu E, Cadwell KK. Frequency and mortality of septic shock in Europe and North America: a systematic review and meta-analysis. Critical care. 2019 Dec;23:1-1.
Angus DC, Van der Poll T. Severe sepsis and septic shock. New England journal of medicine. 2013 Aug 29;369(9):840-51.
Brinkworth JF, Valizadegan N. Sepsis and the evolution of human increased sensitivity to lipopolysaccharide. Evolutionary Anthropology: Issues, News, and Reviews. 2021 Mar;30(2):141-57.
Van Lier D, Geven C, Leijte GP, Pickkers P. Experimental human endotoxemia as a model of systemic inflammation. Biochimie. 2019 Apr 1;159:99-106.
Farhana A, Khan YS. Biochemistry, lipopolysaccharide. StatPearls. Treasure Island (FL) 2023 Apr.
Ikeda T, Ikeda K, Suda S, Ueno T. Usefulness of the endotoxin activity assay as a biomarker to assess the severity of endotoxemia in critically ill patients. Innate immunity. 2014 Nov;20(8):881-7.
Marshall JC, Foster D, Vincent JL, Cook DJ, Cohen J, Dellinger RP, Opal S, Abraham E, Brett SJ, Smith T, Mehta S. Diagnostic and prognostic implications of endotoxemia in critical illness: results of the MEDIC study. Journal of Infectious Diseases. 2004 Aug 1;190(3):527-34.
Fujimori K, Tarasawa K, Fushimi K. Effectiveness of polymyxin B hemoperfusion for sepsis depends on the baseline SOFA score: a nationwide observational study. Annals of Intensive Care. 2021 Dec;11:1-9.
Jarczak D, Kluge S, Nierhaus A. Sepsis—pathophysiology and therapeutic concepts. Frontiers in medicine. 2021 May 14;8:628302.
Opal SM, Laterre PF, Francois B, LaRosa SP, Angus DC, Mira JP, Wittebole X, Dugernier T, Perrotin D, Tidswell M, Jauregui L. Effect of eritoran, an antagonist of MD2-TLR4, on mortality in patients with severe sepsis: the ACCESS randomized trial. Jama. 2013 Mar 20;309(11):1154-62.
Pickkers P, Mehta RL, Murray PT, Joannidis M, Molitoris BA, Kellum JA, Bachler M, Hoste EA, Hoiting O, Krell K, Ostermann M. Effect of human recombinant alkaline phosphatase on 7-day creatinine clearance in patients with sepsis-associated acute kidney injury: a randomized clinical trial. Jama. 2018 Nov 20;320(19):1998-2009.
Coelho MM, Luheshi G, Hopkins SJ, Pela IR, Rothwell NJ. Multiple mechanisms mediate the antipyretic action of glucocorticoids. American Journal of Physiology-Regulatory, Integrative and Comparative Physiology. 1995 Sep 1;269(3):R527-35.
McCoy CE, Carpenter S, Pålsson-McDermott EM, Gearing LJ, O'Neill LA. Glucocorticoids inhibit IRF3 phosphorylation in response to Toll-like receptor-3 and-4 by targeting TBK1 activation. Journal of Biological Chemistry. 2008 May 23;283(21):14277-85.
Singulair (montelukast sodium) US FDA Label 2019.
Maeba S, Ichiyama T, Ueno Y, Makata H, Matsubara T, Furukawa S. Effect of montelukast on nuclear factor κB activation and proinflammatory molecules. Annals of Allergy, Asthma & Immunology. 2005 Jun 1;94(6):670-4.
Samah Mahde*,1 and Sarmad H.Kathem*, Anti-Inflammatory Effect of L-carvone on Lipopolysaccharide-Induced Acute Lung Injury, Iraqi J Pharm Sci, Vol.32( 1 ) 2023.
Khodir AE, Ghoneim HA, Rahim MA, Suddek GM. Montelukast attenuates lipopolysaccharide-induced cardiac injury in rats. Human & experimental toxicology. 2016 Apr;35(4):388-97.
Kang JH, Lim H, Lee DS, Yim M. Montelukast inhibits RANKL-induced osteoclast formation and bone loss via CysLTR1 and P2Y12. Molecular medicine reports. 2018 Aug 1;18(2):2387-98.
Sherwin RL, Garcia AJ, Bilkovski R. Do low-dose corticosteroids improve mortality or shock reversal in patients with septic shock? A systematic review and position statement prepared for the American Academy of Emergency Medicine. The Journal of Emergency Medicine. 2012 Jul 1;43(1):7-12.
Son JY, Kwack WG, Chung EK, Shin S, Choi YJ. Effects of Early Initiation of High-Dose Dexamethasone Therapy on Proinflammatory Cytokines and Mortality in LPS-Challenged Mice. InHealthcare 2022 Jul 4 (Vol. 10, No. 7, p. 1247). MDPI.
Firmal P, Shah VK, Chattopadhyay S. Insight into TLR4-mediated immunomodulation in normal pregnancy and related disorders. Frontiers in immunology. 2020 May 19;11:527120.
Pedicillo MC, De Stefano IS, Zamparese R, Barile R, Meccariello M, Agostinone A, Villani G, Colangelo T, Serviddio G, Cassano T, Ronchi A. The Role of Toll-like Receptor-4 in Macrophage Imbalance in Lethal COVID-19 Lung Disease, and Its Correlation with Galectin-3. International Journal of Molecular Sciences. 2023 Aug 26;24(17):13259.
De Nardo D, Balka KR, Gloria YC, Rao VR, Latz E, Masters SL. Interleukin-1 receptor-associated kinase 4 (IRAK4) plays a dual role in myddosome formation and Toll-like receptor signaling. Journal of Biological Chemistry. 2018 Sep 1;293(39):15195-207.
Rajpoot S, Wary KK, Ibbott R, Liu D, Saqib U, Thurston TL, Baig MS. TIRAP in the mechanism of inflammation. Frontiers in Immunology. 2021 Jul 8;12:697588.
Vázquez-Carballo C, Guerrero-Hue M, García-Caballero C, Rayego-Mateos S, Opazo-Ríos L, Morgado-Pascual JL, Herencia-Bellido C, Vallejo-Mudarra M, Cortegano I, Gaspar ML, de Andrés B. Toll-like receptors in acute kidney injury. International journal of molecular sciences. 2021 Jan 15;22(2):816.
Doaa Adnan Atshan*,1 and Munaf H. Zalzala 2, Possible Protective Effect of Papaverine on ANIT Induce Cholestasis in Rat # Iraqi J Pharm Sci, Vol.32 (Suppl.) 2023.
Khalid Abdulhussein Abdulammer*,1 and Zainab M. Hashim1, Genetic Polymorphism in TNF-α Promoter Region: Its Association with Severity and Susceptibility to Rheumatoid Arthritis in Iraqi Patients with Active Disease, Iraqi J Pharm Sci, Vol.32(2) 2023.
Debets JM, Ruers TJ, Van der Linden MP, Van der Linden CJ, Buurman WA. Inhibitory effect of corticosteroids on the secretion of tumor necrosis factor (TNF) by monocytes is dependent on the stimulus inducing TNF synthesis. Clinical and experimental immunology. 1989 Nov;78(2):224.
Waage A, Bakke O. Glucocorticoids suppress the production of tumor necrosis factor by lipopolysaccharide-stimulated human monocytes. Immunology. 1988 Feb;63(2):299.
Khan S, Wardill HR, Bowen JM. Role of toll-like receptor 4 (TLR4)-mediated interleukin-6 (IL-6) production in chemotherapy-induced mucositis. Cancer Chemotherapy and Pharmacology. 2018 Jul;82:31-7.
Khodabakhsh P, Khoie N, Dehpour AR, Abdollahi A, Ghazi-Khansari M, Shafaroodi H. Montelukast suppresses the development of irritable bowel syndrome phenotype possibly through modulating NF-κB signaling in an experimental model. Inflammopharmacology. 2022 Feb;30(1):313-25.
Alomair BM, Al-Kuraishy HM, Al-Gareeb AI, Al-Hamash SM, De Waard M, Sabatier JM, Saad HM, El-Saber Batiha G. Montelukast and acute coronary syndrome: the endowed drug. Pharmaceuticals. 2022 Sep 14;15(9):1147.
Hardy R, Cooper MS. Bone loss in inflammatory disorders. Journal of Endocrinology. 2009 Jun 1;201(3):309-20.
Vargas SJ, Naprta A, Glaccum M, Lee SK, Kalinowski J, Lorenzo JA. Interleukin‐6 expression and histomorphometry of bones from mice deficient in receptors for interleukin‐1 or tumor necrosis factor. Journal of Bone and Mineral Research. 1996 Nov;11(11):1736-44.
Cottrell J, O’Connor JP. Effect of non-steroidal anti-inflammatory drugs on bone healing. Pharmaceuticals. 2010 May 25;3(5):1668-93.
Canalis E, Bilezikian JP, Angeli A, Giustina A. Perspectives on glucocorticoid-induced osteoporosis. Bone. 2004 Apr 1;34(4):593-8.
Krela-Kaźmierczak I, Szymczak-Tomczak A, Łykowska-Szuber L, Wysocka E, Michalak M, Stawczyk-Eder K, Waszak K, Linke K, Eder P. Interleukin 6, osteoprotegerin, sRANKL and bone metabolism in inflammatory bowel diseases. Advances in Clinical and Experimental Medicine. 2018;27(4):449-53.
Wada N, Maeda H, Yoshimine Y, Akamine A. Lipopolysaccharide stimulates expression of osteoprotegerin and receptor activator of NF-kappa B ligand in periodontal ligament fibroblasts through the induction of interleukin-1 beta and tumor necrosis factor-alpha. Bone. 2004 Sep 1;35(3):629-35.
Pettit AR, Ji H, von Stechow D, Müller R, Goldring SR, Choi Y, Benoist C, Gravallese EM. TRANCE/RANKL knockout mice are protected from bone erosion in a serum transfer model of arthritis. The American journal of pathology. 2001 Nov 1;159(5):1689-99.
Nelson CA, Warren JT, Wang MW, Teitelbaum SL, Fremont DH. RANKL employs distinct binding modes to engage RANK and the osteoprotegerin decoy receptor. Structure. 2012 Nov 7;20(11):1971-82.
Burgener SS, Leborgne NG, Snipas SJ, Salvesen GS, Bird PI, Benarafa C. Cathepsin G inhibition by Serpinb1 and Serpinb6 prevents programmed necrosis in neutrophils and monocytes and reduces GSDMD-driven inflammation. Cell reports. 2019 Jun 18;27(12):3646-56.
Krotova K, Khodayari N, Oshins R, Aslanidi G, Brantly ML. Neutrophil elastase promotes macrophage cell adhesion and cytokine production through the integrin-Src kinases pathway. Scientific reports. 2020 Sep 28;10(1):15874.
Le-Barillec K, Si-Tahar M, Balloy V, Chignard M. Proteolysis of monocyte CD14 by human leukocyte elastase inhibits lipopolysaccharide-mediated cell activation. The journal of clinical investigation. 1999 Apr 1;103(7):1039-46.
Belaaouaj A. Neutrophil elastase-mediated killing of bacteria: lessons from targeted mutagenesis. Microbes and infection. 2002 Oct 1;4(12):1259-64.
Suzuki K, Okada H, Takemura G, Takada C, Kuroda A, Yano H, Zaikokuji R, Morishita K, Tomita H, Oda K, Matsuo S. Neutrophil elastase damages the pulmonary endothelial glycocalyx in lipopolysaccharide-induced experimental endotoxemia. The American journal of pathology. 2019 Aug 1;189(8):1526-35.
Hirche TO, Atkinson JJ, Bahr S, Belaaouaj A. Deficiency in neutrophil elastase does not impair neutrophil recruitment to inflamed sites. American journal of respiratory cell and molecular biology. 2004 Apr;30(4):576-84.
Domon H, Nagai K, Maekawa T, Oda M, Yonezawa D, Takeda W, Hiyoshi T, Tamura H, Yamaguchi M, Kawabata S, Terao Y. Neutrophil elastase subverts the immune response by cleaving toll-like receptors and cytokines in pneumococcal pneumonia. Frontiers in immunology. 2018 Apr 25;9:345207.
Mohammed Ridha Jawad*,1 and Ghaith Ali Jasim2. Pterostilbene Effect on Inflammatory and Oxidation Markers in Benign Prostatic Hyperplasia Rats Model. Iraqi J Pharm Sci, Vol.33(2) 2024.
Downloads
Published
Issue
Section
License
Copyright (c) 2025 Iraqi Journal of Pharmaceutical Sciences
This work is licensed under a Creative Commons Attribution 4.0 International License.
